Telmisartan-induced sprue-like enteropathy: a case report

被引:2
作者
Alzueta, Natalia [1 ]
Echeverria, Amaya [1 ]
Sanz, Lorea [1 ]
Fontela, Carmen [1 ]
Acin, Teresa [1 ]
Montenegro, Lidia [1 ]
Gallon, Javier [1 ]
机构
[1] Serv Navarro Salud Osasunbidea, Pamplona 31001, Spain
关键词
adverse event; angiotensin-receptor II blocker; diarrhea; sprue-like enteropathy; telmisartan;
D O I
10.1136/ejhpharm-2018-001669
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies.
引用
收藏
页码:49 / 51
页数:3
相关论文
共 14 条
[1]  
[Anonymous], EudraVigilance
[2]   Letter: telmisartan associated enteropathy - is there any class effect? Authors' reply [J].
Cammarota, G. ;
Ianiro, G. ;
Bibbo, S. ;
Gasbarrini, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) :570-570
[3]   Letter: telmisartan-associated enteropathy - is there any class effect? [J].
Cyrany, J. ;
Vasatko, T. ;
Machac, J. ;
Nova, M. ;
Szanyi, J. ;
Kopacova, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) :569-570
[4]  
FDA, 2013, DRUG SAF COMM FDA AP
[5]   Systematic review: sprue-like enteropathy associated with olmesartan [J].
Ianiro, G. ;
Bibbo, S. ;
Montalto, M. ;
Ricci, R. ;
Gasbarrini, A. ;
Cammarota, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (01) :16-23
[6]  
KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247
[7]  
Mandavdhare HS, 2017, INTEST RES, V15, P419, DOI 10.5217/ir.2017.15.3.419
[8]   Olmesartan-associated enteropathy: results of a national survey [J].
Marthey, L. ;
Cadiot, G. ;
Seksik, P. ;
Pouderoux, P. ;
Lacroute, J. ;
Skinazi, F. ;
Mesnard, B. ;
Chayvialle, J. A. ;
Savoye, G. ;
Druez, A. ;
Parlier, D. ;
Abitbol, V. ;
Gompel, M. ;
Eoche, M. ;
Poncin, E. ;
Bobichon, R. ;
Colardelle, P. ;
Wils, P. ;
Salloum, H. ;
Peschard, S. ;
Zerbib, F. ;
Meresse, B. ;
Cerf-Bensussan, N. ;
Malamut, G. ;
Carbonnel, F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) :1103-1109
[9]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[10]  
Negro Aurelio, 2017, J Clin Med Res, V9, P1022, DOI 10.14740/jocmr3047w